๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Moderate-to-severe Plaque Psoriasis

Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis NCT06842199Phase 346 sites๐Ÿ“ Hefei๐Ÿ“ Wuhu๐Ÿ“ Beijing Beijing InnoCare Pharma Tech Co., Ltd. ยท Tests: ICP-488 Tablets, ICP-488 Placebo A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis NCT07724366Phase 345 sites๐Ÿ“ Beijing๐Ÿ“ Chongqing๐Ÿ“ Chongqing Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharโ€ฆ ยท Tests: TQH3906 capsules, Deucravacitinib tablets 6 mg, TQH3906 Capsules placebo, Deucravacitinib tablets placebo Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis NCT06696417n/a1 site๐Ÿ“ Shenyang First Hospital of China Medical University ยท Tests: Drug group๏ผšvunakizumab (IL-17A inhibitor) A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis NCT06912165Phase 21 site๐Ÿ“ Nanjing Zhejiang Wenda Pharma Technology LTD. ยท Tests: WD-890 tablet, WD-890 tablet, WD-890 tablet, Placebo Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) NCT07116967Phase 3411 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Phoenix Bristol-Myers Squibb ยท Tests: Deucravacitinib, Ustekinumab A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania NCT07582783n/a20 sites๐Ÿ“ Bรขrlad๐Ÿ“ Brasov๐Ÿ“ Bucharest Janssen Research & Development, LLC A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase โ…ข Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis NCT07672561Phase 31 site๐Ÿ“ Nanjing Zhejiang Wenda Pharma Technology LTD. ยท Tests: Drug:WD-890, Drug: placebo To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital NCT07337434EARLY Phase 11 site๐Ÿ“ Peshawar Syeda Sana Zaman ยท Tests: Methotrexate, Apremilast A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelxยฎ (Bimekizumab) NCT06888193Phase 114 sites๐Ÿ“ Santa Monica๐Ÿ“ South Miami๐Ÿ“ Boston UCB Biopharma SRL ยท Tests: Bimekizumab A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis NCT07038720Phase 11 site๐Ÿ“ Hangzhou Usynova Pharmaceuticals Ltd. ยท Tests: UA026, Placebo A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults NCT07233291Phase 21 site๐Ÿ“ Al Mansurah Ahmed Ibrahim ยท Tests: Oral roflumilast A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis NCT06030076n/a1 site๐Ÿ“ Graz Almirall, S.A. ยท Tests: Tildrakizumab Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis NCT07251998Phase 21 site๐Ÿ“ Shanghai Beijing InnoCare Pharma Tech Co., Ltd. ยท Tests: ICP-332 Tablets, ICP-332 Tablets, ICP-332 Tablets, ICP-332 Placebo Tablets A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis NCT07326813Phase 31 site๐Ÿ“ Shanghai InventisBio Co., Ltd ยท Tests: D-2570 Tablet, BMS-986165 Tablet, Placebo Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis NCT07362017Phase 310 sites๐Ÿ“ Glendale๐Ÿ“ Fremont๐Ÿ“ Miami Vanda Pharmaceuticals ยท Tests: Ponesimod ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis. NCT04347473Phase 41 site๐Ÿ“ East Windsor Psoriasis Treatment Center of Central New Jersey ยท Tests: Ilumya Injectable Product A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis NCT06979453Phase 3132 sites๐Ÿ“ Birmingham๐Ÿ“ Birmingham๐Ÿ“ Phoenix Bristol-Myers Squibb ยท Tests: Deucravacitinib, Placebo Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques NCT05642182Phase 13 sites๐Ÿ“ Pompano Beach๐Ÿ“ Fargo๐Ÿ“ Philadelphia SFA Therapeutics ยท Tests: SFA002, SFA002 A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis NCT07250802Phase 339 sites๐Ÿ“ Chula Vista๐Ÿ“ Fountain Valley๐Ÿ“ Hialeah Takeda ยท Tests: Zasocitinib, Placebo, Zasocitinib A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) NCT06857942Phase 439 sites๐Ÿ“ Phoenix๐Ÿ“ Fountain Valley๐Ÿ“ Fremont Eli Lilly and Company ยท Tests: Tirzepatide A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis NCT07265284Phase 31 site๐Ÿ“ Beijing Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. ยท Tests: IBI112, placebo A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect) NCT06701513n/a48 sites๐Ÿ“ Amiens๐Ÿ“ Angers๐Ÿ“ Argenteuil Bristol-Myers Squibb ยท Tests: Deucravacitinib Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis NCT07130604Phase 31 site๐Ÿ“ Beijing InventisBio Co., Ltd ยท Tests: D-2570, Placebo A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis NCT07129382Phase 1, Phase 211 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Chengde Chipscreen Biosciences, Ltd. ยท Tests: CS32582 capsule๏ผˆlow dose๏ผ‰ or matched placebo, CS32582 capsule๏ผˆhigh dose๏ผ‰ or matched placebo, CS32582 capsule๏ผˆlow dose๏ผ‰,โ€ฆ An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis NCT07449702Phase 239 sites๐Ÿ“ Phoenix๐Ÿ“ North Little Rock๐Ÿ“ Fountain Valley Oruka Therapeutics, Inc. ยท Tests: ORKA-001 A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis NCT07489885Phase 220 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Chula Vista InventisBio Co., Ltd ยท Tests: D-2570 Tablet, Placebo Tablets Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea NCT06258668n/a2 sites๐Ÿ“ Seoul๐Ÿ“ Seoul Bristol-Myers Squibb ยท Tests: Deucravacitinib A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis NCT07234591NA1 site๐Ÿ“ Shanghai Usynova Pharmaceuticals Ltd. ยท Tests: Tyk2 inhibitor, Placebo Modifying PEST for Psoriatic Arthritis Screening NCT06382051NA30 sites๐Ÿ“ Calgary๐Ÿ“ Edmonton๐Ÿ“ Edmonton Novartis Pharmaceuticals ยท Tests: PEST Screening group An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis NCT07879885Phase 21 site๐Ÿ“ Beijing Hansoh BioMedical R&D Company ยท Tests: HS-20137
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy